NMRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neumora Therapeutics Inc (NMRA) is not a strong buy at the moment for a long-term beginner investor. While there are positive developments in its Alzheimer's drug pipeline and hedge fund interest, the technical indicators suggest a bearish trend, and the financial performance is weak with no revenue growth and widening losses. The lack of recent news or significant political/influential trading activity further diminishes the immediate appeal of the stock.
The MACD is negative and expanding, indicating a bearish momentum. RSI is at 18.773, which is oversold, but this could signal a potential bounce only if supported by other factors. The stock is trading below key support levels (S1: 2.622), and moving averages are converging, showing no clear trend reversal.
Hedge funds are significantly increasing their positions, with a 327.95% increase in buying activity last quarter.
Analysts have upgraded the stock and see a blockbuster potential for NMRA-511 in Alzheimer's disease agitation, with a price target of $6-$7.62.
Weak financial performance with no revenue growth and widening losses (-21.77% YoY net income drop).
Bearish technical indicators and lack of upward momentum.
No recent news or significant political/influential trading activity.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income drop of -21.77% YoY to -$56.76M. EPS also declined by -22.22% YoY to -$0.35.
Analysts are optimistic, with upgrades to Outperform and price targets raised to $6-$7.62. Positive Phase 1b results for NMRA-511 in Alzheimer's disease agitation are seen as a major growth opportunity.
